Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Virpax Pharmaceuticals's enterprise value is $-1.51 Mil.
Virpax Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-12.05 Mil. Therefore, Virpax Pharmaceuticals's EV-to-EBITDA for today is 0.13.
The historical rank and industry rank for Virpax Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
VRPX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.13
Current: 0.13
During the past 7 years, the highest EV-to-EBITDA of Virpax Pharmaceuticals was 0.13. The lowest was 0.00. And the median was 0.00.
VRPX's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 12.295
vs VRPX: 0.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Virpax Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Virpax Pharmaceuticals's share price for today is $0.0004.
Virpax Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.943.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRPX vs SYGGF, SCPX, LADX: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Virpax Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virpax Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Virpax Pharmaceuticals's EV-to-EBITDA falls into.
Virpax Pharmaceuticals's current Enterprise Value is $-1.51 Mil.
Virpax Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virpax Pharmaceuticals (VRPX) has a EV-to-EBITDA of 0.13 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Virpax Pharmaceuticals.
Is Virpax Pharmaceuticals' EV-to-EBITDA too high?
Virpax Pharmaceuticals' current EV-to-EBITDA is 0.13. The Biotechnology industry median EV-to-EBITDA is 12.30. Virpax Pharmaceuticals' value of 0.13 is 98.9% below this industry median.
How does Virpax Pharmaceuticals' EV-to-EBITDA compare to SYGGF and SCPX?
Virpax Pharmaceuticals' EV-to-EBITDA of 0.13 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 12.30. Virpax Pharmaceuticals' value of 0.13 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.30, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virpax Pharmaceuticals's current EV-to-EBITDA of 0.13 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Virpax Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virpax Pharmaceuticals's current EV-to-EBITDA is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current EV-to-EBITDA of 0.13. The current EV-to-EBITDA is 0.13 and 98.9% below the Biotechnology industry median of 12.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current EV-to-EBITDA is 0.13 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRPX has been successfully added to your 
